Infectious Disease
HIV-1
0
Pipeline Programs↗
14
Active Trials↗
14
Companies Involved↗
HIV-1 is an early-stage landscape with 0 programs across 14 companies. The most active players are GSK, Gilead, Tibotec Pharmaceuticals, Ireland.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
124
clinical trials
Completed96 · 77%
Terminated7 · 6%
Active, not recruiting6 · 5%
Recruiting5 · 4%
Withdrawn4 · 3%
Not yet recruiting3 · 2%
Other3 · 2%
Clinical Trials
Trial Activity
124 trials
Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir
Recruiting·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 2·NCT06640192·24 enrolled
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
Recruiting·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT06205602·135 enrolled
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
Recruiting·FFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia·Phase 4·NCT06646562·120 enrolled
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
Not yet recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07390955·83 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)